lp-003
mAbexperimental
Clinical trial activity
6 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
4
Phase 3
1
Phase 4
0
Earliest trial started Jul 1, 2021 (NCT06294288)
Timeline
Indications
Mechanism of action
- Immunoglobulin epsilon Fc receptorINHIBITOR
FCER2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07148557 | Phase 1/Phase 2 (Phase 2) | Aug 31, 2025 | Longbio Pharma |
| NCT06604949 | Phase 1 | Nov 30, 2024 | Jiao Tong University, Longbio Pharma |
| NCT07291284 | Phase 3 | Aug 1, 2024 | Longbio Pharma |
| NCT06228560 | Phase 2 | Jan 25, 2024 | Longbio Pharma |
| NCT06046391 | Phase 2 | Jul 6, 2023 | Longbio Pharma |
| NCT06294288 | Phase 1 | Jul 1, 2021 | Longbio Pharma |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Longbio Pharma | For profit | 6 | 6 | 3 | 2021 |
| Jiao Tong University | Academic/Hospital | 1 | 0 | 1 | 2024 |
2 organizations
Page 1 / 1